Clinical Trials Directory

Trials / Terminated

TerminatedNCT03999515

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
3 (actual)
Sponsor
University of Washington · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies how well erdafitinib in combination with abiraterone acetate or enzalutamide works in treating patients with double negative prostate cancer. Erdafitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Testosterone can cause the growth of prostate cancer cells. Abiraterone acetate lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Enzalutamide blocks the use of testosterone by the tumor cells. Giving erdafitinib with abiraterone acetate or enzalutamide may work better in treating patients with prostate cancer compared to abiraterone acetate or enzalutamide alone.

Detailed description

OUTLINE: Patients receive abiraterone acetate orally (PO) once daily (QD) or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days.

Conditions

Interventions

TypeNameDescription
DRUGAbiraterone AcetateGiven PO
DRUGEnzalutamideGiven PO
DRUGErdafitinibGiven PO

Timeline

Start date
2020-04-27
Primary completion
2021-06-06
Completion
2021-06-06
First posted
2019-06-26
Last updated
2023-09-28
Results posted
2023-09-28

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03999515. Inclusion in this directory is not an endorsement.